Skip to main content

Taliglucerase alfa Side Effects

Medically reviewed by Last updated on Apr 14, 2024.

Applies to taliglucerase alfa: intravenous powder for solution.

Serious side effects of Taliglucerase alfa

Along with its needed effects, taliglucerase alfa may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking taliglucerase alfa:

More common

Less common

Other side effects of Taliglucerase alfa

Some side effects of taliglucerase alfa may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Incidence not known

For Healthcare Professionals

Applies to taliglucerase alfa: intravenous powder for injection.


The most frequently reported side effects were headache, arthralgia, pain in extremity, fatigue, nausea, dizziness, pruritus, flushing, abdominal pain, vomiting, back pain, and rash.[Ref]


Very common (10% or more): Vomiting, abdominal pain

Common (1% to 10%): Nausea, diarrhea

Frequency not reported: Gastrointestinal inflammation[Ref]


Very common (10% or more): Hypersensitivity reactions (including anaphylaxis; 29%)

Frequency not reported: Type III immune-mediated fixed drug eruption

Postmarketing reports: Anaphylaxis[Ref]

In clinical trials, hypersensitivity reactions (including anaphylaxis) were reported in 29% of patients; these reactions occurred up to 3 hours after the start of infusion. Serious hypersensitivity reactions (including anaphylaxis) were reported in some patients. In clinical trials, 3% of patients had signs/symptoms consistent with anaphylaxis; these reactions occurred during the infusion.[Ref]


Very common (10% or more): Arthralgia (up to 13%), pain in extremity (up to 10%)

Common (1% to 10%): Back pain, bone pain

Frequency not reported: Muscle spasms[Ref]


Very common (10% or more): Development of anti-drug antibodies (up to 53%), neutralizing antibodies detected (10.3%)[Ref]

Nervous system

Very common (10% or more): Headache (up to 19%)

Common (1% to 10%): Dizziness, paresthesia

Frequency not reported: Tremor[Ref]


Common (1% to 10%): Fatigue, flushing, peripheral edema, infusion reaction, weight increased

Frequency not reported: Chest discomfort, feeling hot[Ref]

Infusion-related reactions occurred most often within 24 hours of the infusion and consisted of arthralgia, headache, vomiting, flushing, pruritus, pain in extremity, pulmonary hypertension, diarrhea, chest discomfort, feeling hot, muscle spasms, tremor, throat irritation, erythema, and rash.[Ref]


Common (1% to 10%): Pruritus, erythema, rash, urticaria[Ref]


Common (1% to 10%): Throat irritation, rhinorrhea, sneezing

Frequency not reported: Pulmonary hypertension[Ref]


Common (1%to 10%): ALT increased[Ref]


Common (1% to 10%): Infusion site pain[Ref]


Common (1% to 10%): Eye pruritus, eye swelling, lacrimation increased[Ref]


1. (2012) "Product Information. Elelyso (taliglucerase alfa)." Pfizer U.S. Pharmaceuticals Group

2. Cerner Multum, Inc. "Australian Product Information."

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.